Because of the varying expression profiles of individual membrane progesterone receptors in prostate cancers during progression from primary androgen-sensitive to CRPC, eventually to NEPC, it is important to understand the biological responses of individual membrane progesterone receptors before applying progestins as an anti-AR therapy in prostate cancer management. This evidence concerns the gene AR and prostate carcinoma.